Nasopharyngeal Cancer Companies are involved in targeted therapeutics development with respective active and inactive ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

Purple Biotech's growing intellectual property portfolio for NT219 in combination with anti-cancer standard-of-care therapies ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-b ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...

The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated ...

Researchers Identify Key Mechanism in Human Lung Development Oct. 31, 2024 — Researchers have shown that the IGFBP3 protein plays a relevant role in human lung development. The results of the ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.